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Abstract 2-methoxyestradiol (2me2), a metabolite of 17β-estradiol (E2), has been tested in
phase II clinical cancer trials and models of inflammation. Its effects are only partly clarified. We
investigated the effects of 2me2 on the immune system, using ovariectomized or sham-operated
mice treated with a high and a low dose of 2me2 (2me2H and 2me2L), E2 or vehicle. We
investigated antagonism of tissue proliferation and estrogen response element (ERE) activation.
Established immunomodulation by E2 was reproduced. 2me2L increased NK and T-cells from
bone marrow, spleen and liver. Both 2me2H and E2 induced uterus proliferation in
ovariectomized mice, but no antagonistic effects on uteri growth were seen in intact animals.
Both E2 and 2me2H activated EREs.
Immunomodulation by 2me2 is tissue-, and concentration dependent. E2 regulated the immune
system more potently. The higher dose of 2me2 resulted in E2 like effects, important to consider
when developing 2me2 as a drug.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).2me2, 2-Methoxyestradiol;
; ERs, Estrogen receptors;
ovx, Ovariectomized; orx,
hritis; SERM, Selective estro-
r Bone and Arthritis Research
and Inflammation Research,
othenburg, Box 480, 405 30
25.
ius@rheuma.gu.se
ma.gu.se (M.C. Erlandsson),
der),
ten).
4.03.011
blished by Elsevier Inc. T
/by-nc-nd/3.0/).his1. Introduction
2-methoxyestradiol (2me2) is an endogenous metabolite
of 17β-estradiol (E2). It exerts anti-angiogenic and anti-
proliferative effects, and has been evaluated in phase II clinical
trials for the treatment of cancers [1–5]. It has also been tested
in animal models of rheumatoid arthritis (RA) [6,7] and,
recently, multiple sclerosis [8]. In thesemodels, 2me2 inhibited
local inflammation, angiogenesis, and leukocyte infiltration, as
well as bone resorption. The mechanisms underlying these
different effects are not clear. 2me2's known mode of actions
includes disrupting microtubules leading to apoptosis, andis an open access article under the CC BY-NC-ND license
41Immune regulation by 2-methoxyestradiolregulation of hypoxia-inducible factor 1α (HIF-1α), active in
inflammatory settings [5].
Estrogens regulate the immune system; both affecting T-,
and B-cells, as well as down regulating NK cell cytotoxicity
[9–14]. In some inflammatory models, many effects of 2me2
resemble actions seen after exposure to E2 [7,15]. E2 is
converted to 2me2 through the P450 system and the
enzyme catechol-O-methyltransferase (COMT). COMT defi-
cient (COMT−/−) mice develop preeclampsia and show
a dysregulation of their decidual NK cells [16]. The
pre-eclampsia was reversed when the COMT−/− mice were
given 2me2. In addition, 2me2 levels are lower in patients
with preeclampsia [16–18]. In a recent study, we presented
data showing that mice lacking COMT have an altered
immune phenotype [19]. This suggests that not only E2, but
also 2me2, can regulate the immune system.
In vitro, 2me2 has a 500-fold lower affinity for the
estrogen receptor α (ERα) than E2 [20]. During pregnancy,
levels of 2me2 increase more than 1000-fold, and there is
conflicting data regarding whether or not administration of
2me2 can lead to ER activation in vivo [7,15,21,22]. ERα
signaling mediates the action of E2 on bone and uterus [23].
In animal models, 2me2 treatment caused uterus prolifera-
tion and bone remodeling, as well as T-cell regulation
[7,15]. Since 2me2 is interesting not only from a physiolog-
ical point of view, but also pharmacologically, there is need
for further studies on estrogen related effects by 2me2. We
therefore studied whether 2me2 exerted immunomodulating
effects in tissues and cells known to respond to E2. In
addition, we tried to elucidate the mechanisms or pathways
behind the effects by giving 2me2 to estrogen response
element-coupled luciferase-mice and treating
estrogen-intact animals with 2me2 in order to investigate
competitive blocking of estrogen receptors.
2. Materials and methods
2.1. Animals and experimental procedures
Female C57/Bl6 mice were purchased from Charles River,
Ry, Denmark. All mice were housed in a temperature-
controlled room with a 06.00–18.00 h light cycle and
consumed a soy-free diet (R70, Lantmännen, Stockholm,
Sweden) and tap water ad libitum. Luciferase reporter mice
coupled to estrogen response elements (ERE-luciferase
mice) enabling in vivo detection of activation of ERE and
classic estrogen signaling were a kind gift from Jan-Åke
Gustafsson and Paul T van der Saag [24]. The Ethics
Committee on Animal Cares and Use in Gothenburg approved
all procedures.
At nine weeks of age, female mice were ovariectomized
(ovx) or sham operated, and male mice were orchidectomized
(orx) under isoflurane (Baxter Medical Ab, Kista, Sweden)
anesthetization by inhalation. Carprofen (Orion Pharma AB,
Animal Health, Sollentuna, Sweden) was administered subcu-
taneously, as postoperative analgesic.
2.2. Drug administration
The dose of 2me2 was chosen based on previous studies
where 2me2 and E2 exhibited anti-inflammatory propertiesin the collagen induced arthritis model, and reduced
atherosclerotic lesions [7,25]. Slow release pellets with
2-methoxyestradiol, 17β-estradiol or vehicle were im-
planted subcutaneously (Innovative Research of America,
Sarasota, FL, USA). Mice were given vehicle, 2me2 low dose
6.66 μg/day (2me2L; 0.4 mg/pellet/60 days), 2me2 high
dose 66.6 μg/day (2me2H; 4 mg/pellet/60 days) or E2
0.83 μg/day (0.05 mg/pellet/60 days). For the sham study,
mice were divided into vehicle, 2me2 low dose 6.66 μg/day
(0.4 mg/pellet/60 days) and E2 (0.05 mg/kg/day). Administra-
tion coincided with the ovx/sham operation, continuing
for three weeks, until mice were terminated. For the ERE-
luciferase study, subcutaneous injections of 17β-estradiol-
3-benzoate (E2; 0.06 mg/kg; Sigma Aldrich, Stockholm, Swe-
den) 2me2 low dose 6.66 μg (2me2L; 0.38 mg/kg), 2me2 high
dose 2me2H; 66.6 μg (3.8 mg/kg) or Miglyoil 812 (Omya
Peralta, Hamburg Germany; 100 μl/mouse) were administered
4 h prior to termination.
2.3. Tissue collection
Mice were terminated three weeks after pellet implanta-
tion. At time of termination, mice were anesthetized with
ketamine (Pfizer AB, Täby, Sweden) and medetomidine
(Orion Pharma AB), bled and killed by cervical dislocation.
Thymus, liver, spleen and uterus were weighed, and then
thymus, spleen and whole bone were put in PBS. The liver
was put into RPMI 1640 (without phenol red, PAA Laborato-
ries GmbH, Pashing, Austria).
2.4. Single cell preparation and
immune-phenotyping by flow cytometry
Single cell suspensions were prepared from the spleen,
thymus, liver, and bone marrow as previously described
[19]. Cells from spleen, marrow, and liver were subjected to
erythrocyte lysis in Tris-buffered 0.83% NH4Cl. All cells were
washed with PBS and put on ice until the total number of
leukocytes was calculated using an automated cell counter
(Sysmex, Kobe, Japan).
Expression of cell surface markers was detected using
fluorochrome conjugated antibodies following Fc-blocking
(anti-mouse CD16/CD32; clone 2.4G2); anti-CD122 FITC
(Clone TM-Beta 1), anti-CD3 PerCp (Clone I45-2C11), anti-
NK1.1 APC (Clone PKI36), anti-CD27 PE (Clone LG.3A10),
anti-Ly49C/I PE (Clone 5E6; BD Biosciences, San Diego, CA,
USA) anti-CD19 PerCp (Clone 6D5; Biolegend, San Diego, CA,
USA). Fluorochrome-minus-one (FMO) was used as control.
Cells were acquired by a FACSCanto II (BD Biosciences)
equipped with Diva Software (BD Biosciences), and data was
further processed using FlowJo software (Three Star, Inc.,
Ashland, VA, USA). Data is presented as percentage positive
and viable leukocytes.
2.5. NK cell cytotoxicity assay
To test NK cells capacity to lyse cells, the NK cell cytotoxic
capability was assayed using the CytoTox 96 non-radioactive
cytotoxicity assay (Promega, Madison, WI, USA) using YAC-1
as target cells, as described previously [19]. Briefly, splenic
NK cells were negatively enriched using the NK Cell Isolation
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Figure 1 Effects on B lymphopoesis: a classic estrogen regulated immune parameter. Nine week old female mice were either ovx or
sham operated and exposed to vehicle, 2me2L (6.66 μg/day), 2me2H (66.6 μg/day), or E2 (0.83 μg/day) for three weeks. The effects
on cell number in the bone marrow (A) were evaluated. B-cell development in the bone marrow was evaluated using FACS and
antibodies against CD19 (B cells; B). C shows a representative FACS plot of CD19+ cells from the bone marrow. Dots represent
individuals; bars represent the arithmetic mean per group. *p b 0.05, ***p b 0.001 versus ovx + vehicle treated mice.
42 A. Stubelius et al.kit (Miltenyi Biotec GmbH, Germany). An effector vs target
ratio of 1:1, 2.5:1 and 10:1 was used. Each sample was
incubated at 37°C in a humidified atmosphere of 5% CO2 for
4 h. The data is presented as “% specific lysis”.2.6. Confocal microscopy
Cells from the cytotoxicity assay (target cells together with
effector cells) were fixed in 2% paraformaldehyde, blocked
with Fc-blocking (BD Biosciences), and stained with biotin
anti-mouse NK1.1 (Biolegend) and streptavidin Alexa Fluor 488
(Life Technologies Europe BV, Bleiswijk, The Netherlands). As
controls, cells were stained with secondary antibody only, or
directly mounted with DAPI excluding both primary and
secondary antibodies. Cells were mounted on slides using
Prolong Gold Antifade Reagent with DAPI (Life Technologies).
Cells were visualized using an LSM 700 confocal microscopeFigure 2 Modulation of T-, and NK cells: proposed 2me2 targete
sham operated and exposed to vehicle, 2me2L (6.66 μg/day), 2me2H
by E2 and 2me2 of T- (CD3+), and NK cells (CD122+CD3−NK1.1+), an
(Ly49C/I) in the bone marrow (A, D, G), spleen (B, E, H), and liver (C,
tested for their ability to lyse YAC-1 cells measuring the release of
representative image of the NK cells together with YAC-1 cells from t
and green cells are stained for NK1.1. In A-I, dots represent individ
scale, and geometric mean on a logged scale. In J, dots represent th
range. *p b 0.05, ** p b 0.01, ***p b 0.001 versus ovx + vehicle treatthrough a 40× plan-NEOFLUAR objective with 2 times
averaging.
2.7. Protein preparation and luciferase analysis
Mice were sacrificed 4 h after injections; organs were
harvested and individually frozen in liquid nitrogen. Protein
preparation and luciferase activity were performed as
previously described, relating activity to amount of protein
[24]. Luciferase activation is proportional to the activation
of gene transcription when ERs bind to EREs and is therefore
considered a measurement of signaling via the classic pathway.
2.8. Statistical analysis
Statistical evaluations were performed using IBM SPSS
Statistics software 22.0.0.0 and GraphPad Prism version
6.0c. One-way ANOVA with Tukey's post hoc test was usedd immune cells. Nine week old female mice were either ovx or
(66.6 μg/day), or E2 (0.83 μg/day) for three weeks. Modulation
NK cell activation receptor (CD27), and an inhibitory receptor
F, I) was evaluated. NK cells from the spleen were enriched and
lactate dehydrogenase as compared to controls (J). K shows a
he cytotoxicity assay. Blue represents nuclear staining with DAPI
uals; bars represent the arithmetic mean per group on a linear
e arithmetic mean of 5–12 mice per group and error bars depict
ed mice.
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Figure 3 Effects of E2 and 2me2 on classic estrogen responsive tissues. Nine week old female mice were either ovx or sham
operated and exposed to vehicle, 2me2L (6.66 μg/day), 2me2H (66.6 μg/day), or E2 (0.83 μg/day) for three weeks. Uterus (A) and
thymus (B) were weighed at termination. Data is presented as % tissue weight of total body weight. Thymus cells were purified and
leukocytes were counted (C). Dots represent individuals; bars represent the arithmetic mean per group on a linear scale, and
geometric mean on a logged scale. ***p b 0.001 versus ovx + vehicle treated mice.
44 A. Stubelius et al.for comparison of three or more independent groups.
Whenever Levene's test revealed unequal variances between
the groups, Dunnett's T3 post hoc test was used instead.
Logarithmic transformations were used when appropriate to
ensure normal distribution of data. ANCOVA was used when
adjustments for covariates were needed, i.e. when two
experiments were pooled. All analyses were two-tailed, and
p values b 0.05 were considered statistically significant.B
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3.1. Immunomodulating effects by 2me2 and E2
3.1.1. B-cell development is affected by E2 and 2me2
Loss of estrogens during menopause, or ovariectomy, leads
to bone loss and affects lymphopoesis [13]. In turn, exposure
to estrogens affects B-cell maturation in the bone marrow,Sh
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Figure 5 Estrogen response elements-coupled luciferase activation by E2 and 2me2. Luciferase activity in tissues was evaluated in
ERE-coupled luciferase orchidectomized (orx) male mice 4 h after exposure to vehicle, 2me2L (6.66 μg), 2me2H (66.6 μg), or E2
(1 μg). Data is presented as luciferase activity after relating to protein content, in (A) bone marrow, (B) spleen, and (C) liver. Dots
represent individuals; bars represent the geometric mean per group. *p b 0.05, ***p b 0.001 versus vehicle treated mice.
45Immune regulation by 2-methoxyestradiolresulting in a diminished CD19+ population [14]. In concor-
dance with previous studies, we could show that ovx led to
an increased amount of cells in the bone marrow (Fig. 1A),
and increased the CD19+-cell population (Fig. 1B and C).
Treatment with 2me2L, 2me2H, and E2 for three weeks
diminished the number of cells in the bone marrow (Fig. 1A)
compared to vehicle. Treatment with both E2 and 2me2H,
but not 2me2L restored the CD19+ cell population equivalent
to sham operated animals (Fig. 1B). In the spleen, B-cells
diminished after treatment with E2, but not 2me2L (vehicle:
56 ± 10%, 2me2L: 52 ± 5%, E2: 48 ± 3% (Mean ±SD). Vehicle
vs. E2: p b 0.05, *; vehicle vs. 2me2L: n.s.).
3.1.2. Peripheral T-, and NK-cells are affected by E2
and 2me2
Previous studies have indicated that both peripheral T-, and
NK cells are targets for 2me2 activity [8,16]. Exposure to E2
for three weeks minimum has also been shown to affect NK
cells and inhibit their cytotoxicity [10,11]. We found that
three weeks of treatment with E2 and both doses of 2me2
produced an expansion of T-cells in the bone marrow and the
liver (Fig. 2A,C). In the spleen however, only the low dose of
2me2 expanded the T-cell population (Fig. 2B). We could also
show that the NK cell population in the bonemarrowdiminished
after ovx and expanded after all treatments (Fig. 2D). The
difference compared with vehicle was statistically significant,
and the magnitude of the response comparable for all three
treatments. In the spleen and liver, only 2me2L expanded the
NK cell population (Fig. 2E,F). To investigate these effects
further, we examined subpopulations of NK cells. We studied
NK cell expression of the activation receptor CD27 in the bone
marrow and spleen, and the inhibitory receptor Ly49C/I in the
liver. CD27 is a tumor necrosis factor (TNF) receptor, and
CD27hi NK cells have increased cytotoxic capacity, producemore cytokines, andmigrate to a higher extent [26]. Since CD27
also has been shown to be part of the developmental steps
for the NK cell, we analyzed this receptor in the bone marrow
as well as in the spleen. Treatment with E2 increased the
expression of CD27 in the bone marrow (Fig. 2G), while the
expression in the spleen decreased (Fig. 2H). The inhibitory
receptor Ly49C/I is implied to convey memory functions of
NK cells specifically in the liver [27]. We found that ovx down
regulated the expression of Ly49C/I, whereas treatment with E2
and 2me2H up regulated the receptor (Fig. 2I).
Following the findings of an expanded NK cell population
by 2me2L in the spleen and a down regulation of CD27 by E2,
we tested the cytotoxic capacity of NK cells from the spleen.
We could repeat the classic E2 down regulation of NK cell
cytotoxicity as previously reported, but we failed to show
any effect by treatment with 2me2 at a low dose (Fig. 2J).3.2. Estrogen signaling by 2me2
3.2.1. Tissue sensitivity for E2 and 2me2 after long-term
administration in ovx animals and intact animals
Most previous studies have focused on mechanisms related
to 2me2's effects on microtubule disruption and have not
taken into account possible activation of ERs. Both the
uterus and the thymus are tissues highly responsive to
estrogen stimulation. Estrogens affect T-cell maturation in
the thymus, where thymic involution is dramatic, and
massive loss of cells ensues. Three weeks after ovx mice
displayed uterus involution (Fig. 3A) and thymic growth
(Fig. 3B). Both treatment with 2me2H and E2 increased
proliferation of the uterus to the same extent (Fig. 3A), and
at the same time induced atrophy of the thymus (Fig. 3B).
Treatment with 2me2L caused uterus proliferation, but less
46 A. Stubelius et al.than in sham-operated animals (Fig. 3A, p = 0.07), and
induced thymic involution (Fig. 3B–C).
3.2.2. 2me2 does not act as an antagonist on ERs
ERα mediates proliferation of the uterus [23]. The effect of a
ligand after binding to ERs, and its following transcriptional
regulation, is a complex systemdepending on interactions with
different co-activators and co-repressors [28]. In fact, selec-
tive estrogen receptor modulators (SERM) can act as antago-
nists on ERs when physiological E2 is present, depending on
recruitment of different co-molecules [29]. We investigated
possible antagonistic effects of 2me2 on estrogen-sensitive
tissues by giving 2me2L, vehicle or E2 to ovary intact sham
operated animals for three weeks. We used only 2me2L as
2me2H resembled E2 effects. Treatment with E2 caused an
increase in body weight (Fig. 4A). However, no antagonistic
effectswere seen after treatmentwith 2me2L on uteri growth,
thymic involution, or liver weight (Fig. 4B–D).
3.2.3. High dose of 2me2 activates estrogen response
elements (ERE) after short-term treatment
The uteri weight after long-term treatment of 2me2 demon-
strates a dose-dependent uterotrophic effect (Fig. 3A). Indeed,
2me2H induced a uterus weight similar to that of mice exposed
to E2 (Fig. 3A). We have previously published data showing that
the high dose of 2me2 can activate ERE to the same extent as
E2 in the uterus [7]. In order to elucidate if 2me2 could activate
EREs also in other organs, in a system devoid of natural
estrogens, orchidectomized male luciferase-ERE reporter mice
were given 2me2L (6.66 μg), or 2me2H (66.6 μg), vehicle, or
E2 (1 μg) 4 h prior to termination. Data show activation of ERE
in bone marrow, spleen and liver after exposure to both E2 and
2me2H (Fig. 5A,B,C). 2me2L only activated EREs in the bone
marrow (Fig. 5A). The same results were seenwhen repeated in
ovx females after administration with E2 and 2me2L (data not
shown).4. Discussion
The purposes of these studies were to investigate the
immunomodulating effects of 2me2, in comparison to those
of E2. Similar to E2, 2me2 is an endogenous steroid, acting
in several tissues on multiple targets [30,31]. 2me2 has
been evaluated in clinical trials of cancers, and models of
different inflammatory diseases. We have identified three
key findings in the presented studies. First, 2me2 is a less
potent immune-modulator than E2. Second, the higher the
concentration of 2me2, the more E2-like effects on immune
cells and estrogen responsive tissues are detected. Finally,
2me2 seems to regulate cells in a tissue-, and dose-
dependent manner.
In our study we have used two doses of 2me2; 2me2L and
2me2H, to investigate its efficacy, and compared these
effects with an established immune-modulatory dose of E2.
These doses of 2me2 were chosen based on our previous
studies showing dose-dependent amelioration of collagen
induced arthritis and underlying inflammation, by both 2me2
doses [7]. The 2me2L dose used in this study is equimolar of
6 μg/day E2, which allowed us not only to study efficacy of
2me2, but also its potency compared to E2.Estrogens affect B lymphopoesis in the bone marrow [14].
We therefore used this model to compare the immune
modulation by E2 and 2me2. Both E2 and 2me2H affected B
lymphopoesis but not 2me2L in the bone marrow (Fig. 1B). In
the spleen, only E2 diminished the B-cell population. We
conclude that E2 affects B lymphopoesis more potently than
2me2.
According to recent publications, 2me2 targets T lym-
phocytes and NK cells [8,16], and long-term treatment with
estrogens can down regulate NK cell cytotoxicity [10,11]. In
our study, we found that both NK-, and T-cells were
regulated equally by both E2 and 2me2 in the bone marrow
(Fig. 2A and D). In the peripheral organs however, a
different pattern could be identified. NK cells in the liver,
and both NK cells and T-cells in the spleen, expanded after
exposure to 2me2L, but not after E2 and 2me2H. However,
only E2 downregulated NK cell cytotoxicity. As suggested by
Hayakawa et al. [26], this reduced killing capacity correlat-
ed to a reduced CD27 expression, thus affecting TNF
mediated functions. Reducing the activation by TNF could
be a mechanism E2 employs to decrease NK cell cytotoxicity.
The inhibitory Ly49C/I receptor on NK cells in the liver was
also downregulated by E2. So even though we see a shift in
the NK cell population by 2me2L, only E2 regulates NK cell
functionality. A recent study found that lower plasma levels
of E2 coincided with an increased tissue concentration of
2me2 [32], suggesting a physiological interplay between the
hormones. This steroid relationship regulated angiogenesis,
and could be an explanation for the found regulation of the
immune response. As higher doses of 2me2 exert similar
actions as E2, it is possible that administration of 2me2H is
converted into E2, thus regulating the immune system as the
more potent form of E2. Then, a lower concentration might
be needed to manifest 2me2's own regulatory effects. In an
E2-free environment, we show that a lower 2me2 concen-
tration did not activate EREs in the spleen and liver, (Fig.
5B–C), and this coincided with a regulation of NK cell
populations, corroborating a regulatory role for lower con-
centrations of 2me2. Based on the consistency of our
findings, we conclude that E2 is a more potent immunomod-
ulator than 2me2. However, 2me2 seems to regulate T-, and
NK cell populations, in a dose and tissue dependent manner.
Mechanistically, ERα-activation leads to some of the side
effects seen in association with hormone replacement
therapy [33]. 2me2 has shown low toxicity when tested in
clinical trials for cancers [2,4], and low affinity for the ERs in
vitro [20]. ERs bind to its ligand in the classic transcription
pathway, form a receptor dimer, and translocate to the
cell nucleus. There they form complexes together with
co-regulatory proteins, and initiate transcription after
binding to estrogen response elements (ERE). This results in
agonism or antagonism, and is a complex system depending
on conformational changes of the receptors and subsequent
recruitment of different co-activators or co-repressors. This
complex system is exploited by the selective estrogen
receptor modulators (SERM) [34]. SERMs distinguish them-
selves from pure agonists as their effects differ in various
tissues, and thereby selectively stimulate or inhibit estrogen
like actions, often in the presence of physiological E2 [35].
Indeed, the SERM Raloxifene is approved as a prophylactic for
invasive breast cancer in the US. We wanted to investigate
possible antagonistic effects after administration of 2me2 in
47Immune regulation by 2-methoxyestradiolthe presence of physiological E2. Based on the findings that
ERα mediates the utero-proliferative effects of E2 [23], and
the thymus and liver are known to respond to E2, we used
these as target organs. We treated ovary-intact mice with
vehicle, E2 and 2me2 for three weeks. Neither the uteri,
thymus, nor liver weights were affected after administration
of 2me2 in intact mice, indicating that 2me2 does not
antagonize ERs in these tissues.
Further, we tested estrogen signaling by 2me2 in mice
with the luciferase reporter gene coupled to EREs. Signaling
through ERE was investigated 4 h after administration to
prevent complete metabolism of 2me2 [36]. We could
detect ERE activation by both E2 and 2me2H in the spleen
and liver. In these organs, the low dose of 2me2 did not
activate ERE. As suggested previously, one possible mecha-
nism for the ER activation seen after 2me2 administration
could be the demethylation of 2me2 into 2-hydroxyestradiol,
followed by conversion back into 17β-estradiol [37–39].
Corroborating the demethylation theory, we found a dose
dependent regulation of 2me2 resembling E2, i.e. the higher
the 2me2 dose, the more E2-like effects. If equilibrium
exists between 2me2 and E2, allowing both hormones to be
present at a specific location, the E2 effects are more
potent. The difference in hierarchy between the hormones
might be a question of affinity to the ERs, or that the
transcriptional activity after ER activation is more potent
than for example HIF-1α signaling, which 2me2 regulates. To
further investigate the demethylation theory, we adminis-
tered an even higher dose of 2me2 to ovx mice for three
weeks, 333 μg/day. At this dose however, the agent was toxic.
To summarize, there are a number of different E2
metabolites whose physiological functions are yet to be
understood. 2me2 functions include anti-angiogenesis,
anti-apoptosis and anti-proliferation [5]. 2me2's role in
inflammation has been investigated either in in vitro
systems, or in in vivo models of inflammation. Here, we
studied the modulation of the immune system after three
weeks with 2me2 at 6.66 μg/day and 66.6 μg/day compared
to E2 0.83 μg/day. We found that 2me2 affected several
immune-competent cells and organs in a dose dependent
way. These effects are consistent with those of E2 in some
organs and target cells, but not uniformly so.5. Conclusions
We conclude that 2me2 has immunomodulatory effects in a
dose dependent way, and the effects are partly similar to
that of E2modulation. As 2me2 has been investigated in clinical
trials of cancer, and is under consideration for clinical trials of
other diseases, it is important to clarify all its potential immune
modulatory properties. Local tissue concentrations of 2me2
could have a physiological immune regulatory role. Based on
our data however, we cannot exclude that pharmacological
doses of 2me2, and exceeding the window of efficacy, could
lead to unwanted estrogen-related effects, which further
studies need to investigate.Declaration of interest
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